India Continuous Glucose Monitoring (CGM) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The india continuous glucose monitoring market size was valued at USD 207.52 million in 2025 and is estimated to grow from USD 231.41 million in 2026 to reach USD 399.69 million by 2031, at a CAGR of 11.55% during the forecast period (2026-2031). This report is Segmented by Component (Sensors, Transmitters, Receivers), Device Type (Real-Time CGM, Intermittently Scanned CGM), Diabetes Type (Type-1, and Type-2), Age Group (Pediatrics, Adults, and Geriatrics), End-User (Hospitals & Clinics, Home-Care Settings, and More). Market Forecasts are Provided in Value (USD).

India Continuous Glucose Monitoring (CGM) Market Trends and Insights

Soaring Diabetes Prevalence & Earlier Diagnosis

India counted 89.8 million adults with diabetes in 2024, and 38.6 million remained undiagnosed, prompting the National NCD Program to scale 724 district clinics that will screen an additional 75 million citizens by March 2025. Updated national guidelines elevate “time in range ≥ 70%” as a therapeutic goal, making continuous rather than episodic monitoring essential. Multicenter trials in 2025 showed FreeStyle Libre lifting TIR from 40.8% to 64.5% among non-insulin-dependent Type-2 patients. Payers face USD 8.5 billion in 2024 diabetes costs, accelerating a pivot toward preventive technologies that curb complications. As a result, new prescriptions for CGM in government and teaching hospitals climbed 22% in 2025, creating a pipeline for the India continuous glucose monitoring market.

Rapid Expansion of Tele-Consult & Digital-Health Programs

The Ayushman Bharat Digital Mission linked 45.38 crore health records by 2024, laying the technical rails for real-time CGM data sharing. Government telemedicine platform e-Sanjeevani logged 270 million sessions, yet only 2% incorporated glucose streams - an adoption gap that start-ups like BeatO are closing through insurer-bundled CGM services. Virtual endocrinology consults now authorize CGM within 4-6 weeks instead of the earlier 6-9 months cycle, compressing demand timelines. Informed-consent modules built into telemedicine workflows reduce prescription friction under the Telemedicine Practice Guidelines 2020. Overall, digitized care pathways increase addressable patients in the India continuous glucose monitoring market by an estimated 1.8 million annually.

High Upfront Device Cost vs SMBG

Abbott sensors cost INR 5,000 per 14 days versus INR 800-2,000 for a glucometer plus strips, making CGM up to 20 times dearer every month. Median annual health spend in Tier-3 cities is USD 60-70, far below the USD 720 needed for continuous isCGM use. EMI options are elusive outside large metros, and credit-card penetration among diabetics in small cities is less than 20%. Consequently, patients use CGM intermittently, dampening per-patient revenue in the India continuous glucose monitoring market.

Other drivers and restraints analyzed in the detailed report include:

• Growing Penetration of Insurance-Led RPM Contracts
• Domestic Sensor Assembly Lowering ASPs
• Patchy Reimbursement Outside Tier-1 Cities

Segment Analysis

Sensors delivered 59.1% of 2025 revenue thanks to their 7-14 day replacement cycle. Receiver demand will expand at 12.34% CAGR as privacy-minded or battery-constrained users choose standalone displays, lifting the India continuous glucose monitoring market size for hardware peripherals without eroding sensor sales. Transmitters face substitution pressure because new integrated designs fuse Bluetooth radio into sensors, eliminating a discrete SKU and trimming total device count.

Margins differ sharply: sensors yield 20-25% gross margins due to high output and discounting, whereas receivers secure 35-40% because of proprietary software tie-ins. Domestic assembly centers on receivers and transmitter shells, leaving high-value electrodes imported from Ireland and Malaysia, a pattern that constrains local value capture. Nonetheless, technology transfer arrangements under the PLI scheme are expected to localize at least 15% of sensor BOM value by 2028, gradually lifting the India continuous glucose monitoring market share of Made-in-India components.

Real-time systems controlled 60.2% of revenue in 2025 because Type-1 insulin users require continuous alerts. Intermittently-scanned devices are projected to surge at 12.11% CAGR as FreeStyle Libre sensors, priced 30-40% lower, win adoption among Type-2 patients seeking lifestyle feedback rather than hypoglycemia warnings. HbA1c studies report a 0.5 point reduction in basal-insulin Type-2 cohorts using isCGM over 90 days, validating its clinical utility.

Pricing dynamics favor isCGM for volume expansion: a 14-day Libre sensor costs INR 5,000, translating to INR 10,700 monthly for continuous wear, 50-60% below monthly rtCGM outlay. Reimbursement pathways also tilt toward isCGM because insurers perceive lower per-member risk. Consequently, isCGM is cannibalizing SMBG far more than rtCGM, and its ascendancy is likely to raise the India continuous glucose monitoring market size for mid-tier offerings

Complete Report Scope:

• By Component
  • Sensors
  • Transmitters
  • Receivers
• By Device Type
  • Real-time CGM (rtCGM)
  • Intermittently-Scanned CGM
• By Diabetes Type
  • Type-1 Diabetes
  • Type-2 Diabetes
• By Age Group
  • Paediatrics
  • Adults
  • Geriatrics
• By End-user
  • Hospitals & Clinics
  • Home-care Settings
  • Sports & Fitness Centres

List of Companies Covered in this Report:

• Abbott Laboratories
• Ascensia
• BeatO (Health Arx)
• Dexcom
• HealthifyMe
• iSprit MedTech (ImageriCGM)
• Medtronic
• Roche
• Terumo India Pvt Ltd
• Truworth Wellness

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support